Sort
10,766 grants matching “checkpoint inhibitor”
Targeting SMARCA2 in SMARCA4-deficient lung cancers in vivo
$557,418Carla P Concepcion-Crisol · Columbia University Health Sciences · R37 · FY2025 · CA
Escape from CAR T surveillance through lineage plasticity
$557,374Patricia A Ernst · University Of Colorado Denver · R01 · FY2025 · CA
Subcellular protein localization in B. subtilis
$557,220Kumaran Ramamurthi · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Molecular Digital CytoImaging for Leukemia Drug Screening
$557,147Tothu Q Vu · Oregon Health & Science University · R01 · FY2022 · CA
Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial
$556,932Lei Zheng · Johns Hopkins University · R01 · FY2022 · CA
Targeting B7-H3 in ovarian cancer
$556,817Gianpietro Dotti · Univ Of North Carolina Chapel Hill · R01 · FY2024 · CA
HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma
$556,762Gopa Iyer · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA
HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma
$556,681Gopa Iyer · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA
Regulation and Function of Stromal Macropinocytosis in Pancreatic Ductal Adenocarcinoma
$556,513Cosimo Commisso · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2024 · CA
Project 2: Targeting STAT3 with an Oral Small Molecule to Treat HCC
$556,316David John Tweardy · University Of Tx Md Anderson Can Ctr · P50 · FY2021 · CA
Quantitative Multimodal Imaging Biomarkers for Combined Locoregional and Immunotherapy of Liver Cancer
$556,171James S Duncan · Yale University · R01 · FY2024 · CA
Targeting FOXP3 mRNA splicing for breast cancer immunotherapy
$555,952Baohua Zhou · Indiana University Indianapolis · R01 · FY2024 · CA
Understanding how adrenergic signaling influences immune contexture of tumors and the efficacy of checkpoint inhibitors
$555,814Elizabeth Repasky · Roswell Park Cancer Institute Corp · R01 · FY2022 · CA
Overcoming racial health disparities in lung cancer through innovative mechanism-based therapeutic strategies
$555,770Wei Zhang · Wake Forest University Health Sciences · R01 · FY2023 · CA
Overcoming racial health disparities in lung cancer through innovative mechanism-based therapeutic strategies
$555,768Wei Zhang · Wake Forest University Health Sciences · R01 · FY2025 · CA
Neutrophil derived proteinases abolish the IFNG signature in NSCLC
$555,585A. McGarry Houghton · Fred Hutchinson Cancer Center · R01 · FY2024 · CA
Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial
$555,474Elizabeth Marion Jaffee · Johns Hopkins University · R01 · FY2025 · CA
Metabolic regulators of Treg/Th17 balance in CNS autoimmunity
$555,180Vijay K Kuchroo · Brigham And Women'S Hospital · R01 · FY2023 · AI
Metabolic regulators of Treg/Th17 balance in CNS autoimmunity
$555,180Vijay K Kuchroo · Brigham And Women'S Hospital · R01 · FY2025 · AI
Metabolic regulators of Treg/Th17 balance in CNS autoimmunity
$555,180Vijay K Kuchroo · Brigham And Women'S Hospital · R01 · FY2024 · AI
Homologous recombination deficiency and beyond in pancreatic cancer: evaluating the regulators of response to pembrolizumab and olaparib (POLAR) from the immune and genomic perspectives
$555,175Eileen Mary O'Reilly · Sloan-Kettering Inst Can Research · P50 · FY2022 · CA
Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma
$554,891Keith D Robertson · Mayo Clinic Rochester · R01 · FY2023 · CA
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
$554,845Kevan C Herold · Yale University · R01 · FY2022 · CA
Chemotherapy and the Bladder Cancer Immune Microenvironment
$554,816William Y Kim · Univ Of North Carolina Chapel Hill · R01 · FY2023 · CA
Chemotherapy and the Bladder Cancer Immune Microenvironment
$554,812William Y Kim · Univ Of North Carolina Chapel Hill · R01 · FY2022 · CA